Skip to main content
Journal cover image

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.

Publication ,  Journal Article
Dubois, CL; Belmans, A; Granger, CB; Armstrong, PW; Wallentin, L; Fioretti, PM; López-Sendón, JL; Verheugt, FW; Meyer, J; Van de Werf, F ...
Published in: J Am Coll Cardiol
October 1, 2003

OBJECTIVES: The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the Assessment of the Safety and Efficacy of New Thrombolytic Regimens (ASSENT-3) trial. BACKGROUND: In the ASSENT-3 trial, co-therapy with abciximab (ABC) or enoxaparin (ENOX) reduced ischemic complications after ST-elevation acute myocardial infarction treated with tenecteplase when compared with unfractionated heparin (UFH). The effect of these new co-therapies on the results of PCI is unknown. METHODS: Clinical outcomes in patients who received co-therapy with ABC, ENOX, or UFH and subsequently underwent an elective (n = 1,064) or urgent (n = 716) PCI in the ASSENT-3 trial were compared. RESULTS: No significant differences in clinical end points were observed in patients who underwent an elective PCI. A non-significant trend toward fewer in-hospital myocardial re-infarctions was seen with ABC and ENOX when compared with UFH (0.5% vs. 0.6% vs. 1.5%, respectively). The incidence of bleeding complications was similar in the three treatment arms. Significantly fewer ABC- and ENOX-treated patients needed urgent PCI compared with UFH (9.1% vs. 11.9% vs. 14.3%; p < 0.0001), but outcomes in these patients were in general less favorable (30-day mortality: 8.2% vs. 5.4% vs. 4.5%; 1-year mortality: 11.0% vs. 8.5% vs. 5.6%; in-hospital re-infarction: 3.9% vs. 2.5% vs. 2.7%; major bleeding complications: 8.8% vs. 7.0% vs. 3.4%). In pairwise comparisons with UFH, the higher one-year mortality and major bleeding rates after ABC were statistically significant (p = 0.045 and p = 0.012, respectively). CONCLUSIONS: Clinical outcomes after elective PCI were similar with the three antithrombotic co-therapies studied in ASSENT-3. Although fewer patients needed urgent PCI with ABC and ENOX, clinical outcomes were less favorable in this selected population, especially with ABC.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

ISSN

0735-1097

Publication Date

October 1, 2003

Volume

42

Issue

7

Start / End Page

1178 / 1185

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Tenecteplase
  • Sweden
  • Survival Analysis
  • Spain
  • Recurrence
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • North Carolina
  • Netherlands
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dubois, C. L., Belmans, A., Granger, C. B., Armstrong, P. W., Wallentin, L., Fioretti, P. M., … ASSENT-3 Investigators. (2003). Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol, 42(7), 1178–1185. https://doi.org/10.1016/s0735-1097(03)00917-3
Dubois, Christophe L., Ann Belmans, Christopher B. Granger, Paul W. Armstrong, Lars Wallentin, Paolo M. Fioretti, José L. López-Sendón, et al. “Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.J Am Coll Cardiol 42, no. 7 (October 1, 2003): 1178–85. https://doi.org/10.1016/s0735-1097(03)00917-3.
Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol. 2003 Oct 1;42(7):1178–85.
Dubois, Christophe L., et al. “Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.J Am Coll Cardiol, vol. 42, no. 7, Oct. 2003, pp. 1178–85. Pubmed, doi:10.1016/s0735-1097(03)00917-3.
Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, López-Sendón JL, Verheugt FW, Meyer J, Van de Werf F, ASSENT-3 Investigators. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol. 2003 Oct 1;42(7):1178–1185.
Journal cover image

Published In

J Am Coll Cardiol

DOI

ISSN

0735-1097

Publication Date

October 1, 2003

Volume

42

Issue

7

Start / End Page

1178 / 1185

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Tenecteplase
  • Sweden
  • Survival Analysis
  • Spain
  • Recurrence
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • North Carolina
  • Netherlands